Long circulating liposomes

Challenges and opportunities

Suyash Deodhar, Alekha K. Dash

Research output: Contribution to journalReview article

Abstract

The poor pharmacokinetic parameters and low solubility of many anticancer therapeutics have warranted the use of drug-delivery systems such as liposomes. Overcoming some drawbacks of the conventional liposomes, targeted liposomal delivery by longer circulation time by addition of poly(ethylene glycol) to the liposomal surface and further adding specific ligands to achieve ligand selective retention and uptake has been introduced. PEGylated liposomes are the only second-generation liposomal formulations in clinical use and are now being challenged with the allergenic response they pose even in the treatment of naive patients. This article will review the challenges and hindrances in the use of long circulating liposomes and explore the opportunities to overcome this issue.

Original languageEnglish (US)
Pages (from-to)857-872
Number of pages16
JournalTherapeutic Delivery
Volume9
Issue number12
DOIs
StatePublished - Nov 1 2018

Fingerprint

Liposomes
Ligands
Ethylene Glycol
Drug Delivery Systems
Solubility
Pharmacokinetics
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Long circulating liposomes : Challenges and opportunities. / Deodhar, Suyash; Dash, Alekha K.

In: Therapeutic Delivery, Vol. 9, No. 12, 01.11.2018, p. 857-872.

Research output: Contribution to journalReview article

@article{2a5c5eb4731548f2980840d543291a4c,
title = "Long circulating liposomes: Challenges and opportunities",
abstract = "The poor pharmacokinetic parameters and low solubility of many anticancer therapeutics have warranted the use of drug-delivery systems such as liposomes. Overcoming some drawbacks of the conventional liposomes, targeted liposomal delivery by longer circulation time by addition of poly(ethylene glycol) to the liposomal surface and further adding specific ligands to achieve ligand selective retention and uptake has been introduced. PEGylated liposomes are the only second-generation liposomal formulations in clinical use and are now being challenged with the allergenic response they pose even in the treatment of naive patients. This article will review the challenges and hindrances in the use of long circulating liposomes and explore the opportunities to overcome this issue.",
author = "Suyash Deodhar and Dash, {Alekha K.}",
year = "2018",
month = "11",
day = "1",
doi = "10.4155/tde-2018-0035",
language = "English (US)",
volume = "9",
pages = "857--872",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "12",

}

TY - JOUR

T1 - Long circulating liposomes

T2 - Challenges and opportunities

AU - Deodhar, Suyash

AU - Dash, Alekha K.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The poor pharmacokinetic parameters and low solubility of many anticancer therapeutics have warranted the use of drug-delivery systems such as liposomes. Overcoming some drawbacks of the conventional liposomes, targeted liposomal delivery by longer circulation time by addition of poly(ethylene glycol) to the liposomal surface and further adding specific ligands to achieve ligand selective retention and uptake has been introduced. PEGylated liposomes are the only second-generation liposomal formulations in clinical use and are now being challenged with the allergenic response they pose even in the treatment of naive patients. This article will review the challenges and hindrances in the use of long circulating liposomes and explore the opportunities to overcome this issue.

AB - The poor pharmacokinetic parameters and low solubility of many anticancer therapeutics have warranted the use of drug-delivery systems such as liposomes. Overcoming some drawbacks of the conventional liposomes, targeted liposomal delivery by longer circulation time by addition of poly(ethylene glycol) to the liposomal surface and further adding specific ligands to achieve ligand selective retention and uptake has been introduced. PEGylated liposomes are the only second-generation liposomal formulations in clinical use and are now being challenged with the allergenic response they pose even in the treatment of naive patients. This article will review the challenges and hindrances in the use of long circulating liposomes and explore the opportunities to overcome this issue.

UR - http://www.scopus.com/inward/record.url?scp=85056638630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056638630&partnerID=8YFLogxK

U2 - 10.4155/tde-2018-0035

DO - 10.4155/tde-2018-0035

M3 - Review article

VL - 9

SP - 857

EP - 872

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 12

ER -